Novel therapeutics for aggressive non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages 1876-1884

  Mahadevan, Daruka ^a   Fisher, Richard I ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ANTINEOPLASTIC AGENT; AT 7519; AZACITIDINE; AZD 7762; BELINOSTAT; BORTEZOMIB; CARFILZOMIB; CD20 ANTIBODY; CEDIRANIB; DASATINIB; ENZASTAURIN; FOSTAMATINIB; IMATINIB; INIPARIB; LENALIDOMIDE; MOCETINOSTAT; NAVITOCLAX; OBATOCLAX; PANOBINOSTAT; PCI 32765; POMALINOMIDE; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; XL 228;

ANGIOGENESIS; ASTHENIA; B LYMPHOCYTE; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER INVASION; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DISEASE MARKER; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TARGETING; EDEMA; EPIGENETICS; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL DISEASE; GENOMICS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOMAGNESEMIA; INFECTION; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; METASTASIS; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PROTEOMICS; RASH; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

ADJUVANTS, IMMUNOLOGIC; APOPTOSIS; CELL PROLIFERATION; CYTOKINES; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, NON-HODGKIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; TOR SERINE-THREONINE KINASES; TUMOR ESCAPE;

EID: 79955802506     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.7171     Document Type: Review

References (70)

1. Feugier P, Van Hoof A, Sebban C, et al. Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
2. Robinson KS, Williams ME, van der Jagt RH, et al: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26:4473-4479, 2008
3. Friedberg JW, Fisher RI: Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am 22:941-952, 2008
4. O'Leary HM, Savage KJ: Novel therapies in peripheral T-cell lymphomas. Curr Hematol Malig Rep 3:213-220, 2008
5. Hartmann EM, Ott G, Rosenwald A: Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am 22:807-823, 2008
6. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
7. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
8. Lindström MS, Wiman KG: Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12:381-387, 2002
9. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2):185-197, 2003 (Pubitemid 37443390)
10. Fernàndez V, Hartmann E, Ott G, et al: Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 23:6364-6369, 2005 (Pubitemid 46218848)
11. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997 (Pubitemid 27167397)
12. Mahadevan D, Spier C, Della Croce K, et al: Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther 4:1867-1879, 2005
13. de Leval L, Bisig B, Thielen C, et al: Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol 72:125-143, 2009
14. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000 (Pubitemid 30046295)
15. Kroemer G, Pouyssegur J: Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 13:472-482, 2008 (Pubitemid 351766797)
16. Luo J, Solimini NL, Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136:823-837, 2009
17. Mahadevan D, Von Hoff DD: Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6:1186-1197, 2007 (Pubitemid 46711982)
18. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002 (Pubitemid 34101731)
19. Friedberg JW, Sharman J, Sweetenham J, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578-2585, 2010
20. Advani R, Sharman JP, Smith SM, et al: Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. J Clin Oncol 28:15s, 2010 (suppl; abstr 8012)
21. Morschhauser F, Seymour JF, Kluin- Nelemans HC, et al: A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 19:247-253, 2008 (Pubitemid 351209293)
22. Robertson MJ, Kahl BS, Vose JM, et al: Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25:1741-1746, 2007 (Pubitemid 46797955)
23. Smith SM, Pro B, Smith S, et al: Molecular inhibition of mTOR with temsirolimus (TORISEL, CCI-779) is a promising strategy in relapsed NHL: The University of Chicago phase II consortium. Blood 108:703a, 2006 (abstr 2483)
24. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356, 2005 (Pubitemid 46206988)
25. Ansell SM, Inwards DJ, Rowland KM Jr, et al: Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 113:508-514, 2008
26. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822-3829, 2009
27. Reeder CB, Gornet MK, Habermann TM, et al: A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL). Blood 110, 2007 (abstr 121)
28. Rizzieri DA, Feldman E, Dipersio JF, et al: A phase 2 clinical trial of deforolimus (AP23573, MK- 8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14:2756-2762, 2008
29. O'Connor OA, Heaney ML, Schwartz L, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173, 2006 (Pubitemid 46630509)
30. Crump M, Coiffier B, Jacobsen ED, et al: Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19:964-969, 2008 (Pubitemid 351627315)
31. Kirshbaum M, Popplewell L, Nademance A, et al: Phase 2 study of vorinostat (suberoylanilide hydroxamic acid) relapse or refractory indolent non-Hodgkin's lymphoma: A California Cancer Consortium study. Blood 112, 2008 (abstr 1564)
32. Younes A, Wedgewood A, McLaughlin P, et al: Treatment of relapsed or refractory lymphoma with an oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study. Blood 110, 2007 (abstr 2571)
33. Wilson WH, O'Connor O, Czuczman MS, et al: Phase I study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies. Blood 112, 2008 (abstr 2108)
34. Hwang JJ, Kuruvilla J, Mendelson D, et al: Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 16:4038-4045, 2010
35. Tolcher AW, Mita A, Lewis LD, et al: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198-5203, 2008
36. Wiernik PH, Lossos IS, Tuscano JM, et al: Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26:4952-4957, 2008
37. Czuczman MS, Vose JM, Zinzani PL, et al: Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results of an international study (NHL-003). Blood 112, 2008 (abstr 268)
38. Zinzani PL, Witzig TE, Vose JM, et al: Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results of an international study (NHL-003). Blood 112, 2008 (abstr 262)
39. Habermann TM, Lossos IS, Justice G, et al: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145:344-349, 2009
40. Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520-525, 2009
41. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005 (Pubitemid 46224166)
42. Heath EI, Bible K, Martell RE, et al: A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59-65, 2008
43. Davis RE, Ngo VN, Lenz G, et al: Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. Nature 463:88-92, 2010
44. Ma S, Rosen ST: Enzastaurin. Curr Opin Oncol 19:590-595, 2007 (Pubitemid 47508866)
45. Mahadevan D: Molecular targeting of oncogenic pathways: The next generation of drugs for cancer therapy. http://emedicine.medscape.com/article/ 1372666-overview
46. Rasheed W, Bishton M, Johnstone RW, et al: Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 8:413-432, 2008 (Pubitemid 351836289)
47. Gerecitano J: The future of small molecule inhibitors in lymphoma. Curr Oncol Rep 11:378-385, 2009
48. Briones J: Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther 9:1305-1316, 2009
49. Relander T, Johnson NA, Farinha P, et al: Prognostic factors in follicular lymphoma. J Clin Oncol 28:2902-2913, 2010
50. Goy A, Ford P, Feldman T, et al: A phase I trial of the pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed/refractory mantle cell lymphoma. Blood 110, 2007 (abstr 2569)
51. Ladetto M, Compagno M, Ricca I, et al: Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood 103:4644-4649, 2004 (Pubitemid 38745997)
52. Chanan-Khan AA, Cheson BD: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26:1544-1552, 2008
53. Wang M, Fayad L, Hagemeister F, et al: A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 25:448s, 2007 (suppl; abstr 8030)
54. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417-421, 2004
55. Staudt LM: Oncogenic activation of NFkappaB. Cold Spring Harb Perspect Biol 2:a000109, 2010
56. Compagno M, Lim WK, Grunn A, et al: Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 459:717-721, 2009
57. Ribrag V, Gisselbrecht C, Haioun C, et al: Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: A randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 115:4540-4546, 2009
58. Leonard JP, Furman RR, Cheung YK, et al: CHOP-R + bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 25:448s, 2007 (suppl; abstr 8031)
59. Dunleavy K, Janik J, Gea-Banacloche J, et al: Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood 104:389a, 2004 (abstr 1385)
60. Wong D, Korz W: Translating an antagonist of chemokine receptor CXCR4: From bench to bedside. Clin Cancer Res 14:7975-7980, 2008
61. De Clercq E: The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 77:1655-1664, 2009
62. Burger JA, Stewart DJ: CXCR4 chemokine receptor antagonists: Perspectives in SCLC. Expert Opin Investig Drugs 18:481-490, 2009
63. O'Connor OA, Horwitz S, Hamlin P, et al: Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357-4364, 2009
64. Piekarz R, Wright J, Frye R, et al: Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood 112, 2008 (abstr 1567)
65. Dueck G, Chua N, Prasad A, et al: Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116:4541-4548, 2010
66. O'Connor OA: Novel Agents in Development for Peripheral T-Cell Lymphoma. Semin Hematol 47:S11-S14, 2010 (suppl 1)
67. Cerchietti LC, Ghetu AF, Zhu X, et al: A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17:400-411, 2010
68. Soucy TA, Smith PG, Milhollen MA, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732-736, 2009
69. Cerchietti LC, Lopes EC, Yang SN, et al: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6 - dependent B cell lymphomas. Nat Med 15:1369-1376, 2009
70. Study of MLN8237 in adults with aggressive non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00807495?term=lymphoma&lead-ex=Y& spons=Millenium&fund=2&rank=8